Nomogram Predicting Survival to Assist Decision-Making of Metastasectomy in Patients With Metastatic Renal Cell Carcinoma

Kan Wu†, Zhihong Liu†, Yanxiang Shao and Xiang Li*

Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Sichuan, China

The survival benefit of metastasectomy (MSX) in patients with metastatic renal cell carcinoma (mRCC) remains unclear. A reliable model to predict an individuals’ risk of cancer-specific mortality (CSM) and to identify optimal candidates for MSX is needed. We identified 2,911 mRCC patients who underwent cytoreductive nephrectomy from the Surveillance, Epidemiology, and End Results database (2010–2015). Based on the Fine and Gray competing risks analyses, we created a nomogram to predict the survival of mRCC patients. Decision tree analysis was useful for patient stratification. The impact of MSX was assessed among three different subgroups. Overall, 579 (19.9%) cases underwent MSX. In the entire patients, the 1-, 2-, and 3-year cumulative incidence of CSM were 32.8, 47.2, and 57.9%, respectively. MSX was significantly associated with improved survival (hazard ratio [HR] = 0.875, 95% confidence interval [CI] 0.773–0.991; P = 0.015). Based on risk scores, patients were divided into three risk groups using decision tree analysis. In the low-risk group, MSX was significantly associated with a 12.8% risk reduction of 3-year CSM (HR = 0.689, 95% CI 0.507–0.938; P = 0.008), while MSX was not associated with survival in intermediate- and high-risk groups. We proposed a novel nomogram and patient stratification approach to identify suitable patients for MSX. The newly identified patient subgroup with a low-risk of CSM might benefit more from aggressive surgery. These results should be further validated and improved by the prospective trials.

Keywords: metastatic renal cell carcinoma, metastasectomy, nomogram, cancer-specific mortality, cytoreductive nephrectomy

INTRODUCTION

Kidney cancer comprises approximately 2% of all malignant tumors and ranks 14th among the most common cancers in the world (1, 2). More notably, about 20–30% of patients present with synchronous metastatic disease at the time of diagnosis, with a poor prognosis (3). In the past decade, the use of targeted therapies against the VEGF and mTOR pathways has significantly improved the survival of patients with metastatic renal cell carcinoma (mRCC) (4). With the
torrential increase in novel immunotherapies largely making these regimens obsolete, as the first-line treatment for mRCC (5).

In addition to modern systemic therapy, cytoreductive nephrectomy also has important value in treating mRCC, allowing a longer survival for well-selected patients with distant disease (6). Of note, metastasectomy (MSX) may also be thought as a potential treatment option to eliminate a large percentage of the tumor burden and sometimes achieve complete remission of the disease (7, 8). Several published studies have shown that surgical excision of the metastases could prolong survival and could be safely done in mRCC patients, even in the presence of multiple metastases (9, 10). Recently, a large hospital-based study based on the National Cancer Database analysis, also suggested that MSX-treated patients had a prolonged survival time when compared to non-MSX treated patients (11).

Obviously, some patients with distant disease may benefit from MSX, but now it is still unclear which subgroups may benefit from aggressive surgery. Proper patient selection strategy has been poorly explored. Therefore, developing a reliable model to identify ideal candidates for MSX is an important consideration. The nomogram is a convenient tool that can quantify survival prediction and has value in patient risk stratification. It has been proved that the prognostic model could provide precise risk prediction in several cancer entities (12, 13). Although several nomograms have been constructed for predicting survival of kidney cancer patients (14–16). The applicable models for guiding mRCC patient to choose MSX are still scant.

Given this background, we used a population-based database to build a prognostic model as a risk stratification strategy, and further determine a patient subgroup who may be more likely to benefit from MSX among mRCC patients.

MATERIALS AND METHODS

Study Population
Data was derived from the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) database, which collects and publishes cancer-specific outcomes for approximately 28% of the American population. Using the SEER database, we identified patients diagnosed with metastatic RCC between 2010 and 2015.

Inclusion criteria included: (1) patients with renal cancer labeled as the ICD-O-3 site codes (C649, 8000-8980); (2) patients who underwent cytoreductive nephrectomy; (3) patients with pathological confirmation; (4) patients aged 18–90 years at initial diagnosis. Patients with missing data on race, distant sites (lung, liver, bone, or brain), T stage, N stage, tumor grade, or survival status were excluded from the cohort. Likewise, cases with bilateral tumors, and those with unknown surgical information were also excluded.

Excision of metastatic lesions included surgical resection to distant lymph nodes, regional and distant sites. Patients were grouped based on treatment type: MSX group versus non-MSX group.

Demographic and Clinical Variables
Study variables included age, sex, race, tumor stage, tumor location, distant site, tumor grade, treatment, survival months, vital status, and cause of death (based on the SEER cause-of-death classification).

Statistical Analysis
Differences in demographic and clinical characteristics were examined using the Chi-square test for categorical variables. A univariate and multivariate Fine and Gray’s competing risk analysis was performed to identify risk factors associated with cancer-specific mortality (CSM) and expressed as a hazard ratio (HR) with 95% confidence interval (CI). Non-kidney cancer-related death was considered as competing risk event for cancer-specific death.

The nomogram for predicting CSM was built in patients who did not receive MSX treatment. The factors with a p value < 0.05 in univariate analysis were further incorporated into multivariate analysis. Independent factors of survival were finally identified using the multivariable competing risks proportional hazards model. A nomogram to predict survival was established based on the factors that included in the final model. Internal validation of the nomogram was performed using the concordance index (C index) value, which was used to estimate the discriminative performance of the model. A calibration curve (1,000 bootstrap resamples) was graphically generated to assess the calibration of the nomogram.

According to the nomogram scores, decision tree analysis (Chi-Square automatic interaction detector) was utilized to identify the cutoff points for building risk classification system. The patients were divided into three prognostic groups: the low-, intermediate-, and high-risk groups.

All statistical analyses were performed with SPSS software version 23.0 (IBM, Armonk, NY, USA) and R software (version 3.5.1; R Foundation). A P value <0.05 in a 2-tailed test was determined as statistical significance.

Ethics Statement
We signed the SEER Research Data Agreement (No. 12587-Nov2019) and further searched the data according to the approved guidelines. The SEER data is available to the public, and patients’ records are anonymous. Therefore, this study was deemed exempt from review by our institutional review board.

RESULTS
Overall, 2,911 eligible patients with mRCC were enrolled in this study. Among them, 579 (19.9%) cases underwent MSX, while 2,332 (80.1%) patients received non-MSX treatment. The median age of the entire patients at first diagnosis was 61 years (interquartile range [IQR] 54–69 years). The baseline characteristics of all patients are summarized in Table 1.
Patients with lower T stage and lymph node stage, or those with bone metastases and brain metastases were more likely to receive MSX. However, lung metastases were relatively less in the MSX (44.2%) patients and more in non-MSX group (60.6%).

Among 2,911 eligible patients, 1,692 (58.1%) patients died of kidney cancer during follow-up period (median time: 17 [IQR 7–32] months). The 1-, 2-, and 3-year cumulative incidence of CSM for all patients were 32.8, 47.2, and 57.9%, respectively. In the non-MSX treated patients, the multivariate competing risks analysis identified T stage, N stage, tumor grade, and distant organs (bone, brain, liver, or lung) as independent factors for CSM (Table 2). All confirmed predictors were integrated to develop a prognostic model for survival (Figure 1). The C index of the novel nomogram was 0.710, reflecting the good discriminative ability of the predictive model. The calibration plots also showed favorable agreement in the 3-year cumulative incidence of CSM between the nomogram-predicted probabilities and the actual observations (Supplementary Figure 1). Each factor in the predictive model was assigned a risk score based on its contribution as presented in the nomogram (Figure 1). According to the sum of points, we can easily estimate the predicted probability of CSM for a patient at each time point.

Besides, based on the total risk scores of each patient in the non-MSX group produced by the novel nomogram, we determined two cut-off values (scores 10.1 and 19.3) by using decision tree analysis (Figure 2), to build a proper risk classification system. Then, all patients were classified into three prognostic groups: patients with a total score <10.1 were sorted into the low-risk group (n = 744), cases with a total score ≥19.3 were classified into the high-risk group (n = 691), and the remaining patients were assigned to the intermediate-risk group (n = 1,476). In the total cohort, these three risk subgroups had a distinct difference in the 3-year cumulative incidence of CSM: 35.6% in the low-risk group, 59.0% in the intermediate-risk group, and 80.4% in the high-risk group, respectively (P < 0.001; Supplementary Figure 2).

For the entire patients, MSX was significantly associated with decreased CSM compared with non-MSX treatment (3-year

### TABLE 1 | Baseline demographic and clinical characteristics of the patients.

| Characteristic                  | No MSX (n = 2,332) | MSX (n = 579) | P value |
|---------------------------------|--------------------|---------------|---------|
| Age, n (%)                      |                    |               |         |
| Median (IQR)                    |                    |               |         |
| ≤75 y                           | 62 (54–69)         | 61 (53–68)    | 0.089   |
| >75 y                           | 2,092 (89.7)       | 533 (92.1)    |         |
| Sex, n (%)                      |                    |               |         |
| Male                            | 1,630 (69.9)       | 413 (71.3)    | 0.500   |
| Female                          | 702 (30.1)         | 166 (28.7)    |         |
| Race, n (%)                     |                    |               |         |
| White                           | 1,951 (83.7)       | 496 (85.7)    | 0.239   |
| Other                           | 381 (16.3)         | 83 (14.3)     |         |
| Laterality, n (%)               |                    |               |         |
| Left                            | 1,256 (53.9)       | 306 (52.8)    | 0.663   |
| Right                           | 1,076 (46.1)       | 273 (47.2)    |         |
| T stage, n (%)                  |                    |               |         |
| T1                              | 288 (12.3)         | 80 (13.8)     | <0.001  |
| T2                              | 286 (12.2)         | 94 (16.2)     |         |
| T3                              | 1,496 (64.2)       | 312 (53.9)    |         |
| T4                              | 263 (11.3)         | 93 (16.1)     |         |
| N stage, n (%)                  |                    |               |         |
| N0                              | 1,634 (70.1)       | 455 (78.8)    | <0.001  |
| N1                              | 698 (29.9)         | 124 (21.4)    |         |
| Bone metastases, n (%)          |                    |               |         |
| No                              | 1,655 (71.0)       | 384 (66.3)    | 0.029   |
| Yes                             | 677 (29.0)         | 195 (33.7)    |         |
| Brain metastases, n (%)         |                    |               |         |
| No                              | 2,196 (94.2)       | 507 (87.6)    | <0.001  |
| Yes                             | 136 (5.8)          | 72 (12.4)     |         |
| Liver metastases, n (%)         |                    |               |         |
| No                              | 2,057 (88.2)       | 507 (87.6)    | 0.669   |
| Yes                             | 275 (11.8)         | 72 (12.4)     |         |
| Lung metastases, n (%)          |                    |               |         |
| No                              | 918 (39.4)         | 323 (55.8)    | <0.001  |
| Yes                             | 1,414 (60.6)       | 256 (44.2)    |         |
| Grade, n (%)                    |                    |               |         |
| Grade 1–2                       | 455 (19.5)         | 98 (16.9)     | 0.174   |
| Grade 3                         | 949 (40.7)         | 258 (44.8)    |         |
| Grade 4                         | 928 (39.8)         | 223 (38.5)    |         |

MSX, metastasectomy; IQR, interquartile range.
cumulative incidence 52.6 vs 59.2%; HR = 0.875, 95% CI 0.773–0.991; P = 0.015; Table 3; Figure 3). In the subgroup analysis (Table 3; Figure 3), MSX was also correlated with a decrease in CSM in the low-risk group (3-year cumulative incidence 25.5 vs 38.3%; HR = 0.689, 95% CI 0.507–0.938; P = 0.008). However, MSX was not correlated with reduced CSM in the intermediate-risk group (3-year cumulative incidence 56.9 vs 59.5%; HR = 0.972, 95% CI 0.823–1.149; P = 0.602), and high-risk group (3-year cumulative incidence 75.6 vs 81.7%; HR = 0.825, 95% CI 0.661–1.030; P = 0.825).

**DISCUSSION**

Advances in contemporary systemic therapy, specifically since the introduction of targeted therapy, have shown a remarkable improvement in survival for patients with mRCC. However, it’s relatively rare to obtain complete remission with targeted agents alone (17), and many patients may suffer from side effects associated with pharmacotherapy. Moreover, the economic burden for mRCC patients is relatively heavy (18). Conversely, the survival benefit from MSX has shown encouraging results, providing a chance to achieve complete remission of the disease and improved survival (19). According to the study by Brecheteau et al., all 22 mRCC patients who experienced a complete remission were treated with cytoreductive nephrectomy. Among them, 21 patients underwent surgery for distant metastases (7).

However, the role of MSX in patients with mRCC remains unclear and has not been well-studied in the era of targeted therapy. Several previous studies on MSX in the targeted therapy era have shown the safety and feasibility of MSX in mRCC patients, and provided a long-term complete remission and favorable prognosis (20–22). However, these studies were considerably constrained by a small number of cases and only a specific group, which resulted in inhibiting their generalization. Indeed, given the absence of prospective clinical trials evaluating the role of MSX, large-scale cohort studies could be used to examine the value of MSX in

**TABLE 2 |** Univariate and multivariate analysis for cancer-specific mortality in non-MSX treated patients.

| Variable     | Univariate |     |     | Multivariate |     |
|--------------|------------|-----|-----|--------------|-----|
|              | HR (95% CI)| P   |     | HR (95% CI)  | P   |
| Age, y       |            |     |     |              |     |
| ≤75          |            |     |     |              |     |
| >75          | 1.02 (0.859–1.220) | 0.80 |     |              |     |
| Sex          |            |     |     |              |     |
| Male         |            |     |     |              |     |
| Female       | 1.14 (1.02–1.28) | 0.022 |     |              |     |
| Race         |            |     |     |              |     |
| White        |            |     |     |              |     |
| Other        | 1.07 (0.928–1.220) | 0.37 |     |              |     |
| Laterality   |            |     |     |              |     |
| Left         |            |     |     |              |     |
| Right        | 0.92 (0.829–1.020) | 0.120 |     |              |     |
| T stage      |            |     |     |              |     |
| T1           |            |     |     |              |     |
| T2           | 1.10 (1.19–1.90) | <0.001 |     | 1.36 (1.07–1.72) | 0.011 |
| T3           | 1.57 (2.33–3.80) | <0.001 |     | 1.90 (1.47–2.46) | <0.001 |
| T4           |            |     |     |              |     |
| N stage      |            |     |     |              |     |
| N0           |            |     |     |              |     |
| N1           | 1.16 (1.65–2.05) | <0.001 |     | 1.55 (1.38–1.74) | <0.001 |
| Bone metastases |            |     |     |              |     |
| No           |            |     |     |              |     |
| Yes          | 1.17 (1.04–1.30) | 0.007 |     | 1.35 (1.20–1.53) | <0.001 |
| Brain metastases |            |     |     |              |     |
| No           |            |     |     |              |     |
| Yes          | 1.56 (1.25–1.95) | <0.001 |     | 1.61 (1.28–2.02) | <0.001 |
| Liver metastases |            |     |     |              |     |
| No           |            |     |     |              |     |
| Yes          | 1.43 (1.21–1.68) | <0.001 |     | 1.25 (1.05–1.49) | 0.012 |
| Lung metastases |            |     |     |              |     |
| No           |            |     |     |              |     |
| Yes          | 1.22 (1.09–1.36) | <0.001 |     | 1.19 (1.06–1.34) | 0.004 |
| Grade        |            |     |     |              |     |
| Grade1–2     |            |     |     |              |     |
| Grade3       | 1.63 (1.39–1.91) | <0.001 |     | 1.42 (1.21–1.68) | <0.001 |
| Grade4       | 2.71 (2.32–3.18) | <0.001 |     | 2.05 (1.86–2.60) | <0.001 |

MSX, metastasectomy; HR, hazard ratio; CI, confidence interval.
patients with metastatic disease. A SEER-based analysis by Palumbo (23) showed that metastasectomy was associated with lower overall mortality risk (median survival 11 vs. 9 months, \( P = 0.002 \)). Recently, a large hospital-based national study found that the significant increases in MSX utilization for metastatic kidney cancer, and patients undergoing MSX did benefit from a prolonging survival, with a 17% risk reduction of death, highlighting the potential value of MSX in the treatment management of mRCC (11). Similarly, in this population-based investigation, we found that MSX was significantly associated with a 6.6% risk reduction in the 3-year cumulative incidence of CSM for patients in the whole mRCC cohort, which further indicated that MSX is of great importance in improving the prognosis of patients with distant disease.

The key issue to consider next is to better understand how clinicians make a decision rationale in selecting patients to undergo MSX or not. In the present study, based on patients’ clinicopathological characteristics, we established a novel nomogram and risk classification system for predicting individuals’ risk of CSM, which can be useful in aiding decision-making of MSX in patients with mRCC. Our finding revealed that patients with favorable biological profile at a lower risk of CSM were more likely to benefit from MSX, with a 12.8% risk reduction of kidney cancer-specific death. However, MSX did not confer any survival advantage in the intermediate-risk, and high-risk groups compared with non-MSX treated patients. Likewise, data from a previous study suggested that the selected patients with favorable risk might benefit from MSX and achieve better survival (24). Notably, the first prospective phase III trial (CARMENA) in the targeted therapy era also showed that mRCC patients with intermediate and poor-risk could not benefit from cytoreductive nephrectomy (25). Therefore, the present predictive model can be used to improve the understanding of the potential role of MSX in the metastatic scenario, and has value in clinical decision-making, patient counseling, and clinical trial design.

From a clinical standpoint, our study showed that MSX could confer a survival benefit for the low-risk patients, rather than patients with an unfavorable oncological profile at higher
risk of CSM, thereby avoiding over- or undertreatment for patients. In addition, all predictive factors included in the prognostic model can be easily extracted from clinical practices. Meanwhile, the C index of the present nomogram for predicting survival was 0.710, which is similar to the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model (C index = 0.70) (16), reflecting its great performance and favorable clinical effect. However, there are many elusive issues on this topic. For one, how to develop a multimodal strategy for mRCC patients by combining MSX with drug therapy. Given the disparate patterns of treatment modalities (26), and the lack of high-level evidence, current guidelines do not include specific recommendations on patient selection in the setting of mRCC (27). Notably, the important upside of our finding is that the potential benefits of MSX depend on patient’s health conditions and tumor characteristics.

In addition to the prediction model for survival, in the present study, risk classification is another pivotal step to identify suitable subgroups for MSX in patients with mRCC. Using decision tree analysis, we developed a proper risk classification strategy, which could satisfactorily separate all patients into three different risk groups with distinct CSM rates. Therefore, our approach included predictive model and decision tree analysis, and demonstrated its great performance in patient stratification, enabling clinicians to conveniently estimate individuals’ risk of CSM and select suitable patients who are more likely to benefit from MSX. This approach may be a meaningful and practical tool for helping tailor individualized treatment.

There are certain limitations in our study. First, although this study based on SEER database covers approximately 28% of the American population, the sample size of MSX group is relatively small, and is limited by the inherent bias of retrospective analysis. Second, there is a lack of information on patient performance status, comorbidities, complications of MSX, which may be used in treatment decision-making. Third, detailed information about targeted therapy and other distant sites are unavailable in the

TABLE 3 | Effect of MSX on cancer-specific mortality according to multivariate analysis in different groups.

| Treatment | 3-year cumulative incidence of CSM, % | P value | HR (95% CI) |
|-----------|--------------------------------------|---------|-------------|
| All patients (n = 2,911) | MSX | 52.6 | 0.015 | 0.875 (0.773–0.991) |
| | no MSX | 59.2 | | |
| Low-risk (n = 744) | MSX | 25.5 | 0.008 | 0.689 (0.507–0.938) |
| | no MSX | 38.3 | | |
| Intermediate risk (n = 1,476) | MSX | 56.9 | 0.602 | 0.972 (0.823–1.149) |
| | no MSX | 59.5 | | |
| High risk (n = 691) | MSX | 75.6 | 0.185 | 0.825 (0.661–1.030) |
| | no MSX | 81.7 | | |

MSX, metastasectomy; CSM, cancer-specific mortality; HR, hazard ratio; CI, confidence interval.

HR in multivariate analysis were adjusted for age, sex, race, tumor stage, tumor location, metastatic sites, tumor grade.
SEER database, which undoubtedly affect the survival of mRCC patients. Fourth, although the information of the metastatic organs was recorded, it was not clear that surgery was performed at that site, and we could not determine whether the patients underwent complete resection. Finally, in this cohort, we could not assess whether patients experienced recurrences or metachronous metastases after MSX. Despite these limitations, we first developed a prognostic nomogram for mRCC to identify suitable patients who could benefit from MSX, which can be conveniently performed in clinical practice.

CONCLUSION

Using the prognostic nomogram and decision tree analysis, we proposed a new approach for individuals’ risk prediction and corresponding risk classification system to identify optimal candidates for MSX among patients with mRCC. We found that patients at low risk of CSM might benefit more from MSX. Conversely, MSX did not confer any survival advantage in intermediate-, or high-risk patients. As a novel model, there is a definite need for a prospective trial to validate and improve the merits of our model.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.

ETHICS STATEMENT

Ethical review and approval was not required for the study on human participants in accordance with the local legislation and institutional requirements. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

AUTHOR CONTRIBUTIONS

KW wrote the draft of the article, did the literature search, and contributed to data collection and analysis. ZL wrote the draft of the article and did the figure editing. YS contributed to data collection and analysis. XL contributed to data interpretation and corrections to the article. All authors contributed to the article and approved the submitted version.
FUNDING
This work was supported by the 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University.

ACKNOWLEDGMENTS
The authors appreciate the Surveillance, Epidemiology, and End Results database in providing high-quality clinical data for our research.

REFERENCES
1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin (2008) 58:71–96. doi: 10.3322/CA.2007.0010
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer (2010) 127:2893–917. doi: 10.1002/ijc.25516
3. Didwaniya N, Edmonds RJ, Fang X, Silberstein PT, Subbiah S. Survival outcomes in metastatic renal carcinoma based on histological subtypes: SEER database analysis. J Clin Oncol (2011) 29:381–1. doi: 10.1200/jco.2011.29.7_suppl318
4. Choueiri TK, Motzer RJ. Systemic Therapy for Metastatic Renal-Cell Carcinoma. New Engl J Med (2017) 376:354–66. doi: 10.1056/NEJMra1601333
5. Wallis CJ, Klaassen Z, Bhindi B, Ye XY, Chandrasekhar T, Farrell AM, et al. First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis. Eur Urol (2018) 74:309–21. doi: 10.1016/j.euro.2018.03.036
6. Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R. European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet (London Engl) (2001) 358:966–70. doi: 10.1016/S0140-6736(01)06103-7
7. Berecheau F, Lebdai S, Carrouget J, Lebigot J, Nedelcu C, Rousselet MC, et al. How Did We Obtain Complete Remission in Patients Who Had Metastatic Renal Cancer in the Era of Targeted Therapies? Ann Surg Oncol (2017) 24:369–74. doi: 10.1245/s10434-016-5857-3
8. Thomas AZ, Adibi M, Borregales LD, Wood CG, Karam JA. Role of metastasectomy in metastatic renal cell carcinoma. Curr Opin Urol (2015) 25:381–9. doi: 10.1097/MOU.0000000000000196
9. Russo P. Multi-modal treatment for metastatic renal cancer: the role of surgery. World J Urol (2010) 28:295–301. doi: 10.1007/s00345-010-0530-x
10. Alt AL, Bourjian SA, Lohse CM, Costello BA, Leibovich BC, Blute ML. Survival after complete surgical resection of multiple metastases from renal cell carcinoma. Cancer (2011) 117:2873–82. doi: 10.1002/cncr.25836
11. Sun M, Meyer CP, Karam JA, de Velasco G, Chang SL, Pal SK, et al. Predictors, utilization patterns, and overall survival of patients undergoing metastasectomy for metastatic renal cell carcinoma in the era of targeted therapy. Eur J Surg Oncol (2018) 44:1439–45. doi: 10.1016/j.ejso.2018.05.026
12. Wang Y, Li J, Xia Y, Gong R, Wang K, Yan Z, et al. Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy. J Clin Oncol (2013) 31:1188–95. doi: 10.1200/JCO.2012.41.5984
13. Luo CX, Zhong XR, Deng L, Xie Y, Hu K, Zheng H. Nomogram Predicting Locoregional Recurrence to Assist Decision-Making of Postnephrectomy Radiation Therapy in Patients With T1-2N1 Breast Cancer. Int J Radiat Oncol Biol Phys (2019) 103:905–12. doi: 10.1016/j.ijrobp.2018.11.005
14. Kattan MW, Reuter V, Motzer RJ, Katz J, Russo P. A postoperative prognostic nomogram for renal cell carcinoma. J Urol (2001) 166:633–7. doi: 10.1016/S0022-5347(05)66077-6
15. Lam JS, Shvarts O, Leppert JT, Pantuck AJ, Figlin RA, Beldegrun AS. Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system. J Urol (2005) 174:466–72; discussion 472; quiz 801. doi: 10.1097/01.ju.0000165572.38887.da
16. Ko JJ, Xie W, Kroeger N, Lee JJ, Rini BL, Knox JJ, et al. The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study. Lancet Oncol (2015) 16:293–300. doi: 10.1016/S1470-2045(14)7222-7
17. Buchler T, Bortleck Z, Poprac H, Pavlik T, Veskova N, Hronzinkova M, et al. Outcomes for Patients with Metastatic Renal Cell Carcinoma Achieving a Complete Response on Targeted Therapy: A Registry-based Analysis. Eur Urol (2016) 70:469–75. doi: 10.1016/j.euro.2015.12.031
18. Kale HP, Mays DP, Nadpara PA, Slattum PW, Paul AK, Carroll NV. Economic burden of renal cell carcinoma among older adults in the targeted therapy era. Urol Oncol (2019) 37(6):356.e19–e28. doi: 10.1016/j.urolonc.2019.01.016
19. Patard JJ, Baumert H, Bansal K, Bernhard JC, Bigot P, Escudier B, et al. [CCAFU Recommendations 2013: Renal cancer]. Prog Urol (2013) 23 Suppl 2: S177–204. doi: 10.1161/S1667-7087(13)70055-1
20. Firek P, Richter S, Jaekel J, Brehmer B, Heidenreich A. Neoadjuvant therapy in renal cell cancer after neoadjuvant therapy with multi-tyrosine kinase inhibitors. Urology A (2012) 51:398–402. doi: 10.1016/j.urotnd.2011-2762-9
21. Karam JA, Rini BI, Varella L, Garcia JA, Dreicer R, Choueiri TK, et al. Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma. J Urol (2011) 185:439–44. doi: 10.1016/j.juro.2010.09.086
22. Rini BI, Shaw V, Rosenberg JE, Kim ST, Chen I. Patients with metastatic renal cell carcinoma with long-term disease-free survival after treatment with sunitinib and resection of residual metastases. Clin Genitourin Cancer (2006) 5:232–4. doi: 10.18616/CGC.2006.n.o42
23. Palumbo C, Pecoraro A, Knipper S, Rosiello G, Tian Z, Shariat SF, et al. Survival and Complication Rates of Metastasectomy in Patients With Metastatic Renal Cell Carcinoma Treated Exclusively With Targeted Therapy: A Combined Population-based Analysis. Anticancer Res (2019) 39:4357–61. doi: 10.21873/anticancer.13604
24. Zaid HB, Parker WP, Safdar NS, Gershman B, Erwin PJ, Murad MH, et al. Outcomes Following Complete Surgical Metastasectomy for Patients with Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. J Urol (2017) 197:44–49. doi: 10.1016/j.juro.2016.07.079
25. Mejean A, Ravaud A, Thezenas S, Colas S, Beauval JB, Bansal K, et al. Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma. New Engl J Med (2018) 379:417–27. doi: 10.1056/NEJMoa1803675
26. Dabestani S, Marconi L, Hofmann F, Stewart F, Lam TB, Canedo J, et al. NCCN Guidelines Insights: Kidney Cancer, Version 2.2020. J Natl Compr Canc Netw (2019) 17:1278–85. doi: 10.6004/jnccn.2019.0054

SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2020.592243/full#supplementary-material

SUPPLEMENTARY FIGURE 1 | Calibration curves showing the probability of CSM between the nomogram prediction and the actual observation. A plot along the 45-degree line would indicate a perfect calibration model in which the predicted probabilities are identical to the actual outcomes. CSM, cancer-specific mortality.

SUPPLEMENTARY FIGURE 2 | Cumulative incidence of CSM for the entire patients in the low-, intermediate-, and high-risk groups. CSM, cancer-specific mortality.